Published April 28, 2026 | Version v1
Dataset Open

BREAKTHROUGH THERAPIES IN TYPE 2 DIABETES: ADVANCED ROLE OF GLP-1 RECEPTOR AGONISTS AND SGLT2 INHIBITORS

Authors/Creators

  • 1. Assistant of the Department of Clinical Sciences Asian International University, Bukhara, Uzbekistan

Description

Type 2 diabetes mellitus (T2DM) is a global health challenge characterized by chronic hyperglycemia and associated complications. Recent therapeutic breakthroughs, particularly GLP-1 receptor agonists and SGLT2 inhibitors, have transformed diabetes management. These agents not only reduce blood glucose levels but also provide cardiovascular and renal protection. This article provides a comprehensive review of their mechanisms, clinical efficacy, combination therapy, and future perspectives in modern diabetes care.

Files

882-885.pdf

Files (196.3 kB)

Name Size Download all
md5:52ba91144c0fb989cfd5824edaaa8ef9
196.3 kB Preview Download

Additional details

References

  • American Diabetes Association. (2024). Standards of Medical Care in Diabetes. Diabetes Care.
  • Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Nature.
  • DeFronzo, R. A. (2009). From the triumvirate to the ominous octet: a new paradigm for type 2 diabetes mellitus. Diabetes.
  • Forbes, J. M., & Cooper, M. E. (2013). Mechanisms of diabetic complications. Physiological Reviews.
  • International Diabetes Federation. (2023). IDF Diabetes Atlas.